Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17888676 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Ran R, et al. (2007) A novel 165-kDa Golgin protein induced by brain ischemia and phosphorylated by Akt protects against apoptosis. Mol Cell Neurosci 36, 392-407 17888676
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S174-p - GOLGA3 (mouse) ▲
Orthologous residues
GOLGA3 (human): S174‑p, GOLGA3 (mouse): S174‑p, GOLGA3 (rat): S134‑p
Characterization
 Methods used to characterize site in vivo:  microscopy-colocalization with upstream kinase, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  HeLa (cervical), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) microscopy-colocalization, co-immunoprecipitation, modification site within consensus motif, transfection of constitutively active enzyme, mutation in upstream enzyme recognition motif S345 is the major site phosphorylated by Akt.
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
PDGF increase
LY294002 PDGF, serum inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  apoptosis, altered
 Comments:  protected against Brefeldin-A-induced apoptosis, but not Fas-mediated apoptosis.
Associated Diseases
Diseases: Alterations: Comments:
ischemia

S385-p - GOLGA3 (mouse) ▲
Orthologous residues
GOLGA3 (human): S389‑p, GOLGA3 (mouse): S385‑p, GOLGA3 (rat): S345‑p
Characterization
 Methods used to characterize site in vivo:  microscopy-colocalization with upstream kinase, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  HeLa (cervical), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) microscopy-colocalization, co-immunoprecipitation, modification site within consensus motif, transfection of constitutively active enzyme, mutation in upstream enzyme recognition motif S345 is the major site phosphorylated by Akt.
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
PDGF increase
LY294002 PDGF, serum inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  apoptosis, altered
 Comments:  protected against Brefeldin-A-induced apoptosis, but not Fas-mediated apoptosis.
Associated Diseases
Diseases: Alterations: Comments:
ischemia


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.